Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Warrant (NQ:SABSW)

0.0105 UNCHANGED
Delayed Quote Updated: 3:58 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Warrant

< Previous 1 2 3 4 Next >
News headline image
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
What's going on in today's session ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Via Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
Presentations will feature encore Phase 1 data highlighting the mechanism of action, redosing potential, and early C-peptide response associated with SAB-142, a fully human multi-specific ATG for Stage... 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
What's going on in today's session ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
Top movers in Friday's session ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Wednesday's session: top gainers and losers ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-09-08: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Gapping stocks in Monday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Top movers in Monday's session ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.